In this episode, we look at CagriSema, a next-generation combination medication that pairs semaglutide with cagrilintide, an amylin analogue. We explain how this dual-pathway approach works, review the impressive phase three clinical trial results showing A1C reductions exceeding two percentage points and weight loss of fifteen to twenty percent, discuss the side effect profile, and explore when this medication might become available. Follow us on social media for updates and more content.